bluuebunny/crossref_metadata_2025 huggingface dataset:
561-P: Family Matters—The Need for a Holistic Approach toward Recruitment and Retention of Culturally Diverse Adults
Authors: GAILLARD TRUDY R. , SHAMBLEY-EBRON DONNA , VACCARO JOAN A. , SWAGGER PHILDRA , NEFF DONNA F. , MORTON CYNTHIA , WEBB FERN
Published: June 2023

Introduction: Participation in diabetes research is essential to lower health disparities; however, recruitment and retention of culturally diverse populations (African American, Caribbean, Hispanic/Latino) remains lower than the general population. The aim of this study was to identify the beliefs in this diverse population concerning types and characteristics of health research that they would consider participation.

Methods: The following study was part of a larger study aimed to explore the impact of intergenerational influence (IGI) and perceptions regarding research recruitment and retention of culturally diverse adults. Participants were recruited via flyer, word of mouth, and our statewide Community Advisory Board. Listening sessions were conducted in dyads of older adults (>65 years) and younger adults (25-64 years). The Theory of Reasoned Action and IGI was the framework used to guide the study. All transcripts were transcribed verbatim. NVivo software© was used for data management.

Results: There were 361 adults who participated (N=181 (>65 years) and N=180 (25-64 years). The most cited health concerns were Alzheimer’s disease, diabetes, and hypertension. Most participants cited personal experiences with diabetes, and the need for research in this area “especially in black and brown neighborhoods.” Solutions to increase research participation were, grass roots approaches with community leaders, churches, civic organizations, and schools. Both groups stated interventions should involve the family, focus on prevention, and lifestyle education.

Conclusions: Studies are needed to evaluate the success of recruitment methods that involve community leaders for outreach, include multiple generations, and focus on education and prevention. Thus, continued outreach to culturally diverse groups incorporating multiple holistic approaches warrants future exploration.

Disclosure

T.R.Gaillard: None. D.Shambley-ebron: None. J.A.Vaccaro: None. P.Swagger: None. D.F.Neff: None. C.Morton: None. F.Webb: None.

Funding

National Institute on Aging (R24AG067951)
575-P: Do Overnight Dips Exist following Afternoon Exercise? Factors Associated with Nocturnal Hypoglycemia in the Type 1 Diabetes Exercise Initiative Pediatric (T1DexiP) Study
Authors: SHERR JENNIFER , BERGFORD SIMON , PATTON SUSANA R. , CLEMENTS MARK A. , CALHOUN PETER , GAL ROBIN L. , RIDDELL MICHAEL
Published: June 2023

Some controlled studies have associated afternoon exercise with a biphasic pattern of hypoglycemia (hypo) risk: during exercise and 7-11hrs later. We explored factors relating to nocturnal hypo following afternoon exercise (12PM-6PM) among youth in the observational T1DexiP study. Youth with T1D (n=203; [mean±SD] age14±2 yrs; HbA1c=7.0± 1.2%; 42% female; T1D duration 5.4±3.9yrs; 12% on MDI and 58% on AID) wore a continuous glucose monitor, an activity monitor and logged activity using the Bant app for 10 days. Repeated measures logistic regression adjusted for bedtime glucose and % time below range (TBR < 70mg/dL) in the prior 24hrs. Of the 833 afternoon exercise sessions, 14% led to nocturnal hypo (≥15 consecutive minutes <70 mg/dL). Median TBR was higher in the 24hrs before exercise in youth who developed nocturnal hypo vs those who did not (3% vs 1%), while pre-exercise glucose level, heart rate, and insulin on board were similar. Nocturnal hypo risk was higher among teens who exercised more often during the study (Table). A trend for lower risk was noted with AID use. Our model revealed that participants who exercised >90 min/day had increased risk of nocturnal hypoglycemia, while AID use may reduce risk. This suggests algorithmically modulated insulin delivery may help to mitigate the impact of afternoon exercise on nocturnal glycemia.

Disclosure

J.Sherr: Advisory Panel; Bigfoot Biomedical, Inc., Insulet Corporation, Medtronic, Vertex Pharmaceuticals Incorporated, Cecelia Health, StartUp Health T1D Moonshot, Consultant; Bigfoot Biomedical, Inc., Insulet Corporation, Medtronic, Lilly, Research Support; Insulet Corporation, Medtronic, NIH - National Institutes of Health, Juvenile Diabetes Research Foundation (JDRF), Speaker's Bureau; Insulet Corporation, Zealand Pharma A/S, Lilly, Medtronic. S.Bergford: None. S.R.Patton: None. M.A.Clements: Consultant; Glooko, Inc., Research Support; Dexcom, Inc., Abbott Diabetes. P.Calhoun: None. R.L.Gal: None. M.Riddell: Advisory Panel; Zealand Pharma A/S, Zucara Therapeutics, Indigo Diabetes, Consultant; Lilly Diabetes, Eli Lilly and Company, Jaeb Center for Health Research, Speaker's Bureau; Dexcom, Inc., Novo Nordisk, Sanofi, Stock/Shareholder; Supersapiens, Zucara Therapeutics. T1dexip study group: n/a.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust; Dexcom, Inc.
590-P: Assessment of a Comprehensive Physical Fitness Index to Predict Future Diabetes Mellitus (DM) and Metabolic Syndrome (MetS)
Authors: SATO TAKAAKI , FUJIHARA KAZUYA , YAMADA MAYUKO H. , YAGUCHI YUTA , YAMAMOTO MASAHIKO , KITAZAWA MASARU , ISHIGURO HAJIME , OSAWA TAEKO , YAMADA TAKAHO , KATO KIMINORI , SONE HIROHITO
Published: June 2023

Impaired muscle strength, balance, and flexibility have been associated with the development of type 2 diabetes and atherosclerosis. A physical score (PS), which integrates these physical fitness indices, could be expected to better predict future metabolic diseases. We investigated the longitudinal relationship between the baseline PS and changes in PS and future DM and MetS. Analyzed were 5,718 persons (4,068 men) aged 30 to 69 y without DM who underwent physical fitness tests. Principal component analysis was performed on the correlation matrix of the physical fitness test results according to age and sex. The PS was defined as the first principal component score. Associations between PSs at the start of observation (year −2), change in the PS two years later (year 0) and the incidence of DM at the end of observation (until year 3) were examined by logistic regression analysis. The same analysis was performed for 5,304 persons (3,729 men) without MetS at baseline. Although no significant difference was found in the incidence of DM, a significant difference was found in the incidence of MetS; odds ratio was 1.39 (1.20, 1.61) for each decrease of 1 in the PS in year −2 and 1.51 (1.18, 1.92) for each decrease of 1 in the change in PS from year -2 to year 0. = Results showed that the PS was a simple and non-invasive predictor of MetS.

Disclosure

T.Sato: None. K.Kato: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. K.Fujihara: None. M.H.Yamada: None. Y.Yaguchi: None. M.Yamamoto: None. M.Kitazawa: None. H.Ishiguro: None. T.Osawa: None. T.Yamada: None.

Funding

Japan Society for the Promotion of Science; Japan Ministry of Health, Labour and Welfare (21K11569)
648-P: Perceptions of Diabetes and Stigma—A Quasi-Experimental, Cross-Sectional Evaluation of Australian Diabetes Campaign Videos
Authors: HOLMES-TRUSCOTT ELIZABETH , HATELEY-BROWNE JESSICA , CHARALAMBAKIS ELIZABETH M. , VENTURA ADRIANA D. , GLENISTER ANNETTE G. , SCIBILIA RENZA , SPEIGHT JANE
Published: June 2023

Aim: To examine the potential negative and positive impacts of, and reaction to, eight Australian National Diabetes Week campaign videos (originally broadcast between 2005 and 2015) among adults with and without diabetes.

Method: Cross-sectional, quasi-experimental, 10-arm online study. A general population sample (n=1023, aged 41±14 years, 60% women) and a diabetes population sample (n=510, aged 52±12 years, 49% women, 78% type 2 diabetes) were recruited via an Australian research panel. Participants were randomly exposed to one of eight diabetes campaign videos (intervention) or allocated to one of two control groups (active or passive). Post-exposure, study-specific scales measured diabetes Misconceptions and Seriousness, General and Diabetes Risk-Reduction Motivation and Self-efficacy, and perceptions of video Stigmatization of diabetes. Scores were compared by condition (intervention vs. control), and by campaign Stigma (high vs. low), separately by cohort (general and diabetes).

Results: Exposure to diabetes campaigns had no significant impact on diabetes perceptions, relative to control, with one exception: a modest effect on General Self-efficacy among the general cohort only (p=0.015; d=-0.19). Those perceiving high campaign Stigma (15%), relative to low Stigma (60%), reported significantly greater diabetes Misconceptions (general: d=1.5; diabetes: d=-1.9) and lower Seriousness (d=0.5; d=0.3), as well as lower General Motivation (d=0.2) but higher Diabetes Risk Reduction Motivation (d=0.3) for the general cohort only.

Conclusion: Single exposure to diabetes campaign videos had seemingly little positive impact on public perceptions. The minority, who perceive them as stigmatising, have greater misconceptions about diabetes, and perceive diabetes as less serious. This novel study has implications for the design and evaluation of future diabetes campaign videos globally.

Disclosure

E.Holmes-truscott: Research Support; Sanofi, AstraZeneca. J.Hateley-browne: None. E.M.Charalambakis: None. A.D.Ventura: None. A.G.Glenister: None. R.Scibilia: Advisory Panel; Ascensia Diabetes Care, Eli Lilly and Company, Roche Diagnostics, Employee; Diabetes Australia, Speaker's Bureau; diaTribe. J.Speight: Research Support; Sanofi, Medtronic, Abbott Diabetes, Lilly, Novo Nordisk A/S, Speaker's Bureau; Sanofi.

Funding

Diabetes Victoria
658-P: Evaluating Financial Incentives as a Tool to Increase Medication Adherence—A Systematic Review and Meta-analysis
Authors: WINBERG DEBRA , TANG TIANGE , RAMSEY ZACHARY , BAZZANO ALESSANDRA N. , LI JIAN , LIN YILU , NAUMAN ELIZABETH , SHI LIZHENG
Published: June 2023

Background: Costs are a barrier to medication adherence in patients living with Type 2 Diabetes (PLWD). Financial incentives may lower costs and increase adherence.

Methods: PubMed, Scopus, and Embase were searched for articles published before March 2022 assessing the impact of financial incentives on medication adherence in PLWD. Search terms included “medication adherence,” “T2D,” “financial incentive,” incentive types, and associated Medical Subject Headings. Two pooled analyses - the mean difference in proportion days covered (PDC) or mean possession ratio (MPR) and the mean difference in percent adherent (PDC/MPR ≥80%) - were conducted. Coehn's d Treatment Effect was calculated for each study using mean difference and standard errors. The overall treatment effect for each pooled analysis was calculated using Bayesian meta-analysis.

Results: The review included 25 studies. Medication adherence always improved in 21 studies, three indicated they increased adherence only in some populations, and incentives had no effect in one study. Figure 1 illustrates the meta-analysis results for studies with appropriate outcome data. Both pooled analyses demonstrate a small but statistically significant increase in adherence due to financial incentives (d=0.02, p<0.01).

Conclusion: Financial incentives have the potential to increase medication adherence to antidiabetic drugs.

Disclosure

D.Winberg: Employee; Janssen Scientific Affairs, LLC. T.Tang: None. Z.Ramsey: None. A.N.Bazzano: None. J.Li: None. Y.Lin: None. E.Nauman: None. L.Shi: None.

Funding

Centers for Disease Control and Prevention (U18DP006523)
676-P: Diabetes Distress, Medical Education, and Gamification in a Pediatric/Young Adult Diabetes Center
Authors: IMAI TAYLOR , NGUYEN TANGELA , STANIC TAMARA S. , DIAZ DOREEN , LOPEZ DANIEL , KINMAN RENEE
Published: June 2023

Purpose: It is well known that children, adolescents, and young adults with diabetes face numerous obstacles to adherence. Diabetes distress can lead to diabetes burnout, which worsens diabetes nonadherence. We initiated diabetes distress screening to determine the impact of diabetes distress on our patients and developed games and animated videos in an attempt to assess diabetes knowledge and decrease visit stress.

Methods: Diabetes patients aged 10 and older were given the two-question diabetes distress screening scale (DDS2) during their routine follow-up visits. Two games were created to play at the beginning of each appointment and two animated medical education videos were created on how to recognize and manage diabetes distress.

Results: A total of 207 patients received DDS2 screening questionnaires. The mean DDS2 score was 5.6 (Type 1, n=178) and 5.5 (Type 2, n=29) out of 12 possible points. Only a weak correlation was found between the DDS2 score and hemoglobin A1C (Type 1:R2=0.34, Type 2:R2=0.18) with essentially no correlation noted between diabetes duration and DDS2 score (Type 1:R2=0.001; Type 2:R2=0.01). Ninety-seven percent of patients liked the “pin the bone on your A1C” game, while 93% enjoyed the medical education quiz game, 80% felt they learned something from it, and 89% felt that it made them more relaxed for their visit.

Conclusions: Diabetes distress can lead to diabetes burnout, thus it is important to identify when present. Our data suggest that distress may sometimes be hidden, hence we should specifically screen for diabetes distress in all our pediatric patients that are tweens and older as no significant correlation was found between DDS2 score, hemoglobin A1C, and duration of diabetes. Therapy can be then directed to ameliorating the stress and burnout associated with living with diabetes while the use of easily created educational games and animated videos can be helpful adjuncts to assess patient knowledge while simultaneously lessening appointment stress.

Disclosure

T.Imai: None. T.Nguyen: None. T.S.Stanic: None. D.Diaz: None. D.Lopez: None. R.Kinman: None.
68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)
Authors: CHAVEZ ALBERTO , MEROVCI AURORA , NEPPALA SIVARAM , CRUZ MORENO LUIS A. , BASKOY GOZDE , ACOSTA FRANCISCA M. , HANSIS-DIARTE ANDREA A. , PUCKETT CURTISS L. , ADAMS JOHN M. , ABDUL-GHANI MUHAMMAD , TRIPLITT CURTIS L. , CERSOSIMO EUGENIO , DEFRONZO RALPH A.
Published: June 2023

Beta cell failure is the key pathophysiologic determinant in progression from PreDM to type 2 diabetes (T2D). Lifestyle modifications frequently are insufficient to prevent T2D onset and drugs that modify disease progression by targeting pathophysiologic defects in PreDM may be required.

Methods: EPIC seeks to answer whether a specific drug provides greater benefit to prevent PreDM progression and to assess the effect of two years of treatment with antidiabetic drugs in 200 individuals with IFG and/or IGT on insulin sensitivity (IS) and beta cell function (BCF). At baseline, participants received 2h-OGTT and two-step hyperglycemic clamp (HC) (+125 and +400 mg/dl) with GLP-1RA infusion. Subjects then were randomized to metformin (MET), pioglitazone (PIO), saxagliptin (SAXA) or dapagliflozin (DAPA). 55 participants have completed the intervention (35F/20M; age = 51 ± 3 ys) Matsuda Index of IS was quantitated from OGTT. Beta Cell Function (BCF) was quantitated: (i) from OGTT as (ΔC-Pep/ΔG) x (Matsuda) and (ii) from HC as ΔC-Pep (First Phase, AIR x Matsuda; ΔC-Pep (Second Phase, +400 mg/dL x Matsuda; and (Second Phase + Exenatide) x Matsuda.

Results: A1c did not change significantly in any group, while FPG (106 ±4 to 100 ± 3 mg/dl) and 2h PG (150 ±8 to 141 ± 11) decreased significantly in all groups (p<0.05 for PIO > SAXA). Matsuda Index increased in all groups (p<0.01 for PIO vs all other groups). Weight increased significantly in PIO (+2.5kg p<0.05), did not change with SAXA, decreased with DAPA and MET (both p = NS). BCF during OGTT tended to increase in all groups (p<0.10 for trend). No significant changes in AIR, second phase (+400 mg/dl), and second phase (+400) + Exenatide were seen for MET, SAXA, DAPA, but significantly increased with PIO (AIR 7.1 to 22.8; 2ND STEP 10 to 45.4; 2nd STEP + Exenatide 19 to 79 (all p <0.01).

Conclusion: Early drug intervention in prediabetes with pioglitazone preserves beta cell function and improves insulin sensitivity better than MET, SAXA, and DAPA.

Disclosure

A. Chavez: None. A. Merovci: None. S. Neppala: None. L. A. Cruz Moreno: None. G. Baskoy: None. F. M. Acosta: None. A. A. Hansis-Diarte: None. C. L. Puckett: None. J. M. Adams: None. M. Abdul-Ghani: None. C. L. Triplitt: Speaker's Bureau; Novo Nordisk. E. Cersosimo: None. R. A. DeFronzo: Speaker's Bureau; AstraZeneca. Advisory Panel; AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Novo Nordisk. Research Support; AstraZeneca, Boehringer-Ingelheim, Merck & Co., Inc.

Funding

National Institutes of Health (R01DK024092-3AZ, ISSDAPA0002)
696-P: Evaluating REACHOUT—A Mobile App That Delivers Peer-Led Mental Health Support to Adults with Type 1 Diabetes
Authors: TANG TRICIA S. , KLEIN GERRI , GÖRGES MATTHIAS , FISHER LAWRENCE , POLONSKY WILLIAM H. , HESSLER DANIELLE M. , TAYLOR DEANNE
Published: June 2023

Introduction: Recent years have witnessed a dramatic shift toward digital health technologies for mental health care delivery. While research investigating digital interventions involving peer support for children and adolescents with type 1 diabetes (T1D) has been growing, few, if any studies, have examined peer support mental health interventions for adults with T1D.

Methods: We recruited 46 adults with T1D (M age= 43.9, females=71.7%) living in rural and remote communities in British Columbia to participate in REACHOUT, a 6-month intervention utilizing a mobile app to deliver three modalities of support: one-on-one with a peer supporter, group-based text messaging, and video group sessions. Participants were invited to select their own peer supporter and encouraged to access any or all of the three modalities as frequently as desired. Assessments were conducted at baseline and six months and measured diabetes distress (and seven distress subscales), depressive symptomatology, and perceived support from family/friends, peers, and the health care team. Independent mixed-effects regression models were run to examine pre-post intervention changes.

Results: Thirty-eight participants completed the intervention (attrition = 17%). At six months, reductions were observed for overall distress (p=0.007) and four subscales: powerlessness (p=0.009), management distress (p=0.001), negative social perceptions (p=0.023), and eating distress (p=0.032). For secondary outcomes, depressive symptoms decreased (p=0.009) while perceived support from family/friends (p=0.023) and peers (p<0.001) increased.

Conclusions: Participation in REACHOUT was associated with improvements in diabetes distress as well as other psychosocial outcomes. By offering different modalities of support delivery over a digital platform, participants, especially those living in more geographically marginalized communities, can customize support to meet their own unique needs.

Disclosure

T.S.Tang: Research Support; Juvenile Diabetes Research Foundation (JDRF), Speaker's Bureau; Abbott Diabetes, Insulet Corporation. G.Klein: None. M.Görges: Research Support; Careteam Technologies, IDENTOS, Smile CDR Inc., SecureKey Technologies Inc., Thrive Health, Excelar Technologies. L.Fisher: Consultant; Abbott Diabetes, Eli Lilly and Company, Research Support; Ascensia Diabetes Care. W.H.Polonsky: Consultant; Abbott Diabetes, Boehringer Ingelheim and Eli Lilly Alliance, Eli Lilly and Company, Insulet Corporation, Intuity Medical, Inc., MannKind Corporation, Provention Bio, Inc., Sanofi-Aventis U.S., Vertex Pharmaceuticals Incorporated. D.M.Hessler: Consultant; Lilly. D.Taylor: None.

Funding

JDRF (2-SRA-2020-986-S-B)
699-P: Neighborhood Disadvantage and Psychosocial Health for Parents of Teens with Type 1 Diabetes (T1D)
Authors: O'DONNELL MAEVE B. , SCOTT SAMANTHA R. , ELLISOR BRITNEY M. , GARCIA PEREZ SAMANTHA , ROJAS YULIANA , MALIK FAISAL , HILLIARD MARISA E. , YI-FRAZIER JOYCE P.
Published: June 2023

Background: The psychosocial health of parents is important to the mental and physical health of teens with T1D, yet living in an area of high neighborhood disadvantage may risk parental psychosocial health due, in part, to increased exposure to stressors and less available support. We explored associations among neighborhood disadvantage and parents’ self-reported psychosocial outcomes among racially, ethnically, and socioeconomically diverse parents of teens with T1D.

Methods: At baseline of a 2-site psychosocial intervention trial, 130 parents of teens aged 13-18 with T1D reported on demographic information and their diabetes distress, family conflict, diabetes-related quality of life, and resilience. We retrieved area deprivation index (ADI) scores for home addresses; this measure of neighborhood disadvantage summarizes neighborhood-level income, education, employment, and housing quality via a state-relative decile score ranging from 1-10 (higher scores indicate more disadvantage). Regression analyses were used to examine associations among ADI and psychosocial measures.

Results: 130 parents (2% American Indian/Alaska Native, 2% Asian, 8% Black/African American, 10% Latino/Mexican/South or Central American, 81% White; 87% mothers; 73% employed full-time; 78% private Insurance; 59% college graduate or higher) completed surveys. Mean ADI was 3.8±2.7 (range 1-10). Higher neighborhood disadvantage was associated with significantly higher diabetes distress [F(1,127)=13.99, p<.001] and family conflict [F(1,126)=19.42, p<.001] and lower resilience [F(1,127)=4.30, p=.04] and diabetes-related quality of life [F(1,125)=10.42, p=.002].

Conclusions: Consistently poorer psychosocial health among parents in areas with higher neighborhood disadvantage highlights the centrality of social determinants of health to families of teens with T1D. Targeted support for parents in these areas may benefit family T1D management and, ultimately, youth outcomes.

Disclosure

M.B.O'donnell: None. S.R.Scott: None. B.M.Ellisor: None. S.Garcia perez: None. Y.Rojas: None. F.Malik: None. M.E.Hilliard: None. J.P.Yi-frazier: None.

Funding

National Institutes of Health (R01DK121224)
712-P: Social Support, eHealth Literacy, and mHealth Use in Older Adults with Diabetes—Moderated Mediating Effect of Perceived Importance of App Design
Authors: KIM MINJIN , KIM BEOMSOO , PARK SUNHEE
Published: June 2023

Mobile healthcare (mHealth) for older adults with diabetes could benefit diabetes self-management. However, limited research is available regarding the factors influencing mHealth use. This descriptive study aimed to identify the factors that influence mHealth use. Participants aged 65 years or older with diabetes living in South Korea were recruited online and offline to complete a structured self-report questionnaire. With 252 valid responses, the moderated mediating effect of eHealth literacy and the perceived importance of app design in the relationship between social support and mHealth use were tested using SPSS PROCESS Macro 4.0. The results show that social support had a positive relationship with mHealth use, and eHealth literacy and perceived importance of app aesthetics had a moderated mediating effect. Moreover, when patients’ perceived importance of app aesthetics was high, eHealth literacy more positively affected mHealth use. This study implies that it is necessary to enlist the help of family, friends, and neighbors to increase access to internet-based health information and encourage mHealth use among older adults with diabetes. Furthermore, this study suggests developers should consider user experience (UX), such as font size, color, and menu configuration when developing mHealth for older adults with diabetes.

Disclosure

M.Kim: None. B.Kim: None. S.Park: None.
73-LB: Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes—An Indirect Treatment Comparison
Authors: PANTALONE KEVIN M. , TOFE SANTIAGO , FAN LUDI , PAIK JIM S. , RANTA KARI T. , SAPIN HELENE , OSUMILI BEATRICE
Published: June 2023

Semaglutide (sema) 0.5 mg is part of type 2 diabetes (T2D) standard of care as initial maintenance dose. While there has been a study conducted on TZP and sema 1.0 mg, showing TZP superiority, currently there is no head-to-head study comparing TZP and sema 0.5 mg. Therefore, the objective of this analysis was to evaluate the efficacy and safety of TZP and sema 0.5 mg using adjusted indirect comparisons.

Adjusted indirect comparisons were performed using the Bucher method to compare the relative efficacy and safety of TZP 5, 10, 15 mg and sema 0.5 mg via a common comparator (sema 1.0 mg) based on trial results from SURPASS-2 (TZP vs sema 1.0 mg) and SUSTAIN 7 (sema 0.5 and 1.0 mg vs dulaglutide 0.75 and 1.5 mg).

All TZP doses showed statistically significant greater reductions in HbA1c, weight and BMI from baseline to week 40 compared to sema 0.5 mg (Figure).

TZP demonstrated a comparative safety profile for adverse events (AEs) but patients had statistically significant greater odds of treatment discontinuations due to AEs for TZP 10 and 15 mg. All TZP doses demonstrated no statistically significant differences vs sema 0.5 mg in the odds or likelihood of gastrointestinal AEs.

In these adjusted indirect comparisons the extent of differences between TZP and sema 0.5 mg regarding HbA1c and weight reductions provide insights on their comparative effectiveness in the absence of a head-to-head study.

Disclosure

K. M. Pantalone: Consultant; AstraZeneca, Bayer Inc., Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Bayer Inc., Merck & Co., Inc., Novo Nordisk, Twin Health, Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Merck & Co., Inc., Novo Nordisk. S. Tofe: Advisory Panel; Lilly, Novo Nordisk, Research Support; Lilly, Novo Nordisk, Speaker's Bureau; Lilly, Novo Nordisk. L. Fan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. J. S. Paik: None. K. T. Ranta: Employee; Eli Lilly and Company. H. Sapin: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. B. Osumili: Employee; Eli Lilly and Company.

Funding

Eli Lilly and Company
731-P: The Effect of Abatacept upon Glucose and C-Peptide Endpoints at One Year of Treatment and on Follow-up
Authors: SIMS EMILY K. , RUSSELL WILLIAM E. , HEROLD KEVAN C. , SOSENKO JAY
Published: June 2023

The TrialNet abatacept randomized-controlled trial tested for the ability to delay the progression of T1D in Stage 1 [multiple autoantibody (Ab) positive and normal glucose on OGTT] individuals aged 6-45. No drug effect was detected on the primary endpoint of either dysglycemia or T1D (whichever came first). Based on evidence that C-peptide-based metabolic measures are more specific for T1D and detect an early impact of disease-modifying therapy, we performed post-hoc analyses using these variables and stratified on baseline metabolic profiles. In participants with lower baseline metabolic risk (Index60 <0.00) we assessed if changes in metabolic measures would differ between treatment groups. A favorable effect was evident for the combined glucose and C-peptide endpoints within 1 year of treatment (Table). Next we compared individuals with Index60<0.00 at baseline for exceeding an Index60 threshold of 1.00 on follow-up. 5-year risks were 38.9% for the placebo and 21.1% for the abatacept groups (p=0.016). In summary, for Stage 1 individuals with low baseline metabolic risk, combined glucose and C-peptide endpoints can detect a favorable abatacept effect at 1 year and, more conventionally, a decreased T1D progression risk on follow-up. Future trials of abatacept or other agents in Stage 1 T1D should include combined glucose and C-peptide measures as pre-specified endpoints.

Disclosure

E.K.Sims: Speaker's Bureau; Medscape, American Diabetes Association. W.E.Russell: None. K.C.Herold: Board Member; NexImmune, Consultant; Provention Bio, Inc. J.Sosenko: None.
733-P: Diabetes Remission Outcomes Protocol (DROP)—Early Observation
Authors: KIBAA KARIM , DHAVER SHILTON E. , JOHNSON COLLEEN , VOTTA JENNIE L. , SHAHAR JACQUELINE I. , MITCHELL CHRISTINE , BEATON JOAN M. , SALAH TAREQ , AL-BADRI MARWA , KHATER ABDELRAHMAN , MCCARRAGHER RYAN , HAMDY OSAMA
Published: June 2023

A 12-week multidisciplinary intensive lifestyle intervention (ILI) was shown to induce diabetes remission (A1C <6.5%, on no medications for ≥3 months), particularly among participants with short diabetes duration. Diabetes remission was also achieved with very low-calorie diet (VLCD) or bariatric surgery. Diabetes Remission Outcomes Protocol (DROP) at Joslin Diabetes Center is an ILI designed to induce diabetes remission in patients with type 2 diabetes who meet 3 criteria: 1- duration of diabetes <5 years, 2- A1C <8%, 3- On up to 2 antihyperglycemic medications, but no insulin. It involves two phases: an intervention phase for 12 weeks and a maintenance phase for 9 months. During intervention phase, participants follow a time-restricted fasting for 16 hours and VLCD (800-1000 Kcal/day). Participants also receive cognitive behavioral support and perform exercises designed to maintain lean muscle mass (LMM). They stop all diabetes medications at the beginning of the program and are monitored by CGM. Reintroduction of medications is suggested if glucose time in range (70-180 mg/dL) (TIR) drops to <70%. During maintenance phase, participants return to 1500-1800 calorie diet with the aim of maintaining weight loss and diabetes remission. We tested feasibility of DROP in a pilot of 5 participants with mean age of 52.8±11.4 years, diabetes duration of 13.2±11.8 months, and A1C of 6.44±0.3% on 2 medications. By the end 12-weeks, average weight loss was 19.9 lbs (8.1%). A1C decreased to 6.14±0.48% (p=0.02) on no medications and TIR was 98%. LMM /total body weight significantly increased by 0.03±0.02 (p=0.03). Patient-reported quality of life measures showed significant improvements in the World Health Organization-5 Well-Being Index (p=0.03), Diabetes Distress Scale-17 (p=0.05) and 36-Item Short Form Survey (p=0.04) submodules. DROP is promising approach to induce diabetes remission and improve patients’ quality of life in selected patients with type 2 diabetes. Larger cohorts should be evaluated for longer duration.

Disclosure

K.Kibaa: None. A.Khater: None. R.Mccarragher: None. O.Hamdy: Advisory Panel; Abbott Nutrition, Nemaura Medical, L-Nutra Inc., Twin Health, Consultant; Sanofi, Research Support; Novo Nordisk, Eli Lilly and Company, Gilead Sciences, Inc., Stock/Shareholder; Healthimation. S.E.Dhaver: None. C.Johnson: None. J.L.Votta: None. J.I.Shahar: None. C.Mitchell: None. J.M.Beaton: None. T.Salah: None. M.Al-badri: None.
742-P: Diabetes Prevention Effect of Practically Applicable Intervention in Clinical Settings Based on the Korean Diabetes Prevention Study (KDPS)
Authors: CHON SUK , JIN YUN SOO , WOO JEONG-TAEK ,   THE KOREAN DIABETES PREVENTION STUDY INVESTIGATORS
Published: June 2023

Background: The Korean Diabetes Prevention Study (KDPS, NCT02981121), a national clinical study to prevent T2DM, started in 2016 and is currently ongoing. This study was to evaluate the preventive effect of KDPS intervention for up to 1 year.

Methods: The enrollment criteria are adults aged 30-70 with a BMI ≥ 23 kg/m2 at high risk of T2DM. Three Intervention methods are hospital-based lifestyle modification (hLSM) developed by Korean Diabetes Association, metformin (MET, 250mg~1000mg) and control standard management (STM) including a visit to the doctor every 6 months. LSM consists of 4 times individual diet interventions and lifestyle modification to keep 10 healthy habits with 7 times on-site and 8 times on phone-call contact. We assessed FPG and A1c every 6 months and OGTT every 12 months to check DM progression.

Results: A total of 1611 subjects at 15 university hospitals performed screening with 75g OGTT (KDPS 1: 2016.11 ~ 2018.12, KDPS 2: 2020.9 ~ 2022.4). Eight hundred forty-four patients (male 44.2%) were randomized. The mean age was 56.1 years, BMI 26.6 kg/m2, WC 91.2 cm, FPG 103.2 mg/dL, PP2G 154.9 mg/dL, A1c 5.9%, and there was no significant difference between the three groups. KDPS 2 had a short follow-up period, thus DM prevention effect of up to 1 year was analyzed in 485 subjects of KDPS 1. Up to 1 year, the cumulative incidence of DM was 12/100 person-years (PY) in the LSM, 18/100 PY in MET, and 27/100 PY in STM (P=0.1440). Compared to STM, HR for T2DM in LSM was 0.51 (P=0.0508), and the HR in the MET was 0.82 (P=0.5205).

Conclusion: The KDPS was intended to evaluate the DM prevention efficacy of the intervention methods practically applicable in clinical settings in Korea. The hLSM tended to have a 49% DM prevention effect compared to the STM. However, in the case of the MET, there was no significant difference from the control group. Further full analysis of KDPS results is needed for long term effect.

Disclosure

S.Chon: None. S.Yun: None. J.Woo: None. The korean diabetes prevention study investigators: n/a.

Funding

Korean Disease Control and Prevention Agency (2020-ER6402-00)
746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint
Authors: JI LINONG , AHMANN ANDREW , AHRÉN BO , CAPEHORN MATTHEW , HU PING , LINGVAY ILDIKO , LIU WENYAN , RODBARD HELENA W. , SHEN ZEWEI , SORLI CHRISTOPHER H.
Published: June 2023

Hyperglycemia, high BP and dyslipidemia are common risk factors for CVD. The aim of this study was to assess the proportion of participants treated with once-weekly (OW) semaglutide, or a comparator, achieving a metabolic composite target endpoint in the SUSTAIN trials. Participants from SUSTAIN 1-5, 7-10 and SUSTAIN China with uncontrolled T2D treated with OW semaglutide vs comparators (incl. placebo) were pooled, and the proportion achieving the endpoint (HbA1c <7%, BP <140/90 mmHg and non-HDL cholesterol <130 mg/dL) was assessed. Endpoints were analyzed using on treatment without rescue medication data for each trial, using a binomial logistic regression model with treatment, region/country, and stratification factor as fixed effects and baseline value (HbA1c/BP/Non-HDL) as covariate. Pooled analysis was conducted using logistic regression with treatment and trial as fixed effects and baseline value as covariate. Treatment with 0.5 and 1 mg OW semaglutide was associated with higher odds (OR range 1.4-24.4) of achieving the endpoint vs comparators (Figure). The proportion of participants reaching the composite endpoint across all trials was 24% and 32% for 0.5 mg and 1.0 mg semaglutide, respectively, vs 11% for comparators (p<0.0001). The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D.

Disclosure

L.Ji: Other Relationship; Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc., Bayer Inc., Sanofi-Aventis U.S., Roche Pharmaceuticals, MSD Life Science Foundation, AstraZeneca, Boehringer Ingelheim Inc., Abbott, Metronics. C.H.Sorli: Employee; Acerus Pharmaceuticals. A.Ahmann: Advisory Panel; Medtronic. B.Ahrén: Speaker's Bureau; Novo Nordisk, Nestlé Health Science, Stock/Shareholder; Novo Nordisk, AstraZeneca, Eli Lilly and Company. M.Capehorn: Advisory Panel; Novo Nordisk, Lilly Diabetes, Boehringer Ingelheim Pharmaceuticals Inc., Research Support; Boehringer Ingelheim Inc., Novo Nordisk, Lilly, Speaker's Bureau; Novo Nordisk, Lilly, Boehringer Ingelheim Inc. P.Hu: Employee; Novo Nordisk (China). I.Lingvay: Advisory Panel; Novo Nordisk A/S, Lilly Diabetes, Boehringer-Ingelheim, Sanofi, Consultant; Carmot Therapeutics, Inc., Merck Sharp & Dohme Corp., Janssen Scientific Affairs, LLC, Pfizer Inc., Intercept, Intarcia, Valeritas, TargetRWE, Shionogi, Zealand Pharma, Structure, Bayer, Research Support; Novo Nordisk A/S, Boehringer-Ingelheim. W.Liu: Employee; Novo Nordisk (China). H.W.Rodbard: Advisory Panel; Merck Sharp & Dohme Corp., Pacira BioSciences, Inc., Research Support; Eli Lilly and Company, Medtronic, Sanofi, Novo Nordisk. Z.Shen: Employee; Novo Nordisk (China).
759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy
Authors: CUSI KENNETH , GASTALDELLI AMALIA , FERNANDEZ LANDO LAURA , LIU MINZHI , TORCELLO-GOMEZ AMELIA , RODRÍGUEZ ÁNGEL
Published: June 2023

Patatin-like phospholipase 3 (PNPLA3) I148 genetic variant is highly associated with nonalcoholic fatty liver disease. Tirzepatide (TZP), a novel GIP/GLP-1 receptor agonist, significantly reduced liver fat content (LFC) vs insulin degludec (IDeg) in a subpopulation of patients in the SURPASS-3 phase 3 trial. This post-hoc analysis evaluated changes from baseline to Week 52 in LFC and cardiometabolic parameters by presence of PNPLA3 I148 allele (yes [genotype CG/GG] or no [genotype CC]).

Insulin-naïve patients with type 2 diabetes inadequately controlled on metformin with/without SGLT-2i and fatty liver index ≥60 at baseline had an MRI scan performed prior to randomization (1:1:1:1) to once-weekly TZP (5, 10, 15 mg) or IDeg. LFC was assessed with MRI.

Patients (mean baseline age, 56.2 years; diabetes duration, 8.3 years; HbA1c, 8.2%; weight, 94.4 kg; BMI, 33.5 kg/m2; 30% on SGLT-2i) experienced greater reductions in LFC, weight, HbA1c, and overall greater improvement in lipids profile and liver enzymes with all doses of TZP than with IDeg regardless of the presence of PNPLA3 I148 allele (Table). Findings with TZP were consistent in both subgroups.

In summary, TZP led to clinically meaningful improvements in several cardiometabolic parameters in patients with type 2 diabetes regardless of the presence of PNPLA3 I148 allele.

Disclosure

K. Cusi: Research Support; Echosens, Inventiva. Consultant; Poxel SA. Research Support; LabCorp, Zydus. Consultant; Altimmune, Arrowhead Pharmaceuticals, Inc., AstraZeneca, 89bio, Inc., Bristol-Myers Squibb Company, Lilly, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Medscape, Myovant, Novo Nordisk, ProSciento, Quest Diagnostics, Sagimet, Sonic Incytes, Terns. A. Gastaldelli: Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Pfizer Inc. Consultant; Fractyl Health, Inc. Advisory Panel; Novo Nordisk, Merck Sharp & Dohme Corp., Boehringer Ingelheim International GmbH. Other Relationship; Pfizer Inc. Consultant; Merck Sharp & Dohme Corp. L. Fernandez Lando: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Liu: Consultant; Eli Lilly and Company. A. Torcello-Gomez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Á. Rodríguez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.

Funding

Eli Lilly and Company
760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist
Authors: MAO TING , MENG QINGHUA , ZHANG HAIZHEN , ZHANG JINQIANG J. , SHI SONGTING , GUAN ZHIBO , JIANG XINGLONG , ZHANG FANG , LEI HUI , LIN XICHEN
Published: June 2023

Peptidic glucagon-like peptide 1 receptor agonists (GLP-1RAs) are established treatments for patients with Type 2 Diabetes Mellitus (T2DM) and obesity. However, the need for injection and cold chain storage may limit the utility of most peptidic GLP-1RAs. An oral small molecule GLP-1RA that offers enhanced bioavailability and stability could be more convenient and accessible to patients. Here we report the discovery of GSBR-1290, a highly potent, orally available, novel small molecule GLP-1RA and the characterization of its in vitro and in vivo pharmacology profiles. GSBR-1290 is a small molecule GLP-1RA with high binding affinity to human GLP-1R. GSBR-1290 strongly activated GLP-1R Gαs cAMP pathway without inducing measurable β-arrestin recruitment signaling, which indicates it is a fully biased agonist. The insulin secretion stimulation effect of GSBR-1290 was evaluated in a functional human pancreatic beta cell line, in which GSBR-1290 showed dose dependent induction of insulin secretion. The in vivo efficacy of GSBR-1290 on insulin secretion, glucose control and food intake were evaluated in nonhuman primates (NHPs). In an acute intravenous glucose tolerance test (ivGTT), a single dose of GSBR-1290 strongly induced insulin secretion and glucose clearance. In a repeated dosing study, GSBR-1290 administered orally once daily for 7-day demonstrated robust increase in insulin secretion and glucose clearance in ivGTT and a dose dependent reduction of food intake and body weight. Overall, GSBR-1290 demonstrated potent in vivo efficacy in stimulating insulin secretion, improving glucose tolerance, and reducing food intake and body weight. In conclusion, GSBR-1290 is a highly potent, orally available, fully biased GLP-1RA. Human clinical trials are underway to further evaluate GSBR-1290 as a potential therapy for T2DM and obesity.

Disclosure

T.Mao: Employee; Structuretx. X.Lin: Employee; Structure Therapeutics. Q.Meng: Employee; Beijing Stonewise Technology, Structure Therapeutics Inc. H.Zhang: Employee; Structuretx. J.J.Zhang: Employee; Structure Therapeutics Inc. S.Shi: Employee; Structure Therapeutics Inc. Z.Guan: Employee; Structure Therapeutics. X.Jiang: Employee; Structure Therapeutics. F.Zhang: Employee; Structure Therapeutics, Eternity BioSciences, Stock/Shareholder; Novo Nordisk. H.Lei: Employee; Structure Therapeutics.
763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
Authors: HE KUN , WEI FANG , CHEN HONG , ZHANG YANYAN , SHENG ZHEN , WEN QING
Published: June 2023

Background: Accumulating evidences suggest that dual GLP-1/GIP receptor agonist can achieve prominent glycemic control and body weight loss. Here we report the results of a phase 1 SAD and MAD study of HRS9531 in healthy subjects (NCT05152277).

Methods: In the SAD, healthy subjects were randomized (4:1) to receive subcutaneous injection of HRS9531 (0.1, 0.3, 0.9, 2.7, 5.4, and 8.1 mg) or placebo. In the MAD, healthy subjects were randomized (4:1) to receive HRS9531 (0.9, 2.7, and 5.4 mg [2.7/2.7/4.0/5.4 mg titration]) or placebo once a week for 4 wks. The primary endpoints for both parts were safety and tolerability.

Results: Sixty and 30 subjects were recruited into SAD and MAD respectively. The most common adverse events were abdominal distension and nausea in SAD, and urine ketone body present and nausea in MAD; all considered mild to moderate in severity (mostly mild). No severe hypoglycemia or serious events occurred. Drug exposure were proportional to dose from 0.9-8.1 mg. The median Tmax and mean t1/2 were 48-72 h and 156-182 h in SAD, and 48-72 h and 169-192 h after the fourth dosing in MAD, respectively. Fasting plasma glucose (FPG) levels decreased dose-dependently after single and multiple dosing. The 0 to 2 h glucose AUC during oral glucose tolerance test (OGTT) on D23 decreased dose-dependently relative to placebo in MAD. In SAD, body weight loss was dose-dependent and the maximal mean loss on D8 was 3.8 kg (4.9%) in 8.1 mg group. In MAD, the mean weight loss on D29 (after 4 wks treatment) ranged 4.3-7.7 kg (6.7%-9.3%) across 0.9-5.4 mg groups, and maximal loss (8.0 kg, 10.0%) occurred on D36 in 5.4 mg group.

Conclusions: HRS9531 was well tolerated, had favorable PK, and led to evident glucose decrease and body weight loss. These data support further clinical development of HRS9531 for metabolism-related disorders such as T2DM and obesity.

Disclosure

K.He: None. F.Wei: None. H.Chen: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y.Zhang: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Z.Sheng: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Q.Wen: None.

Funding

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
770-P: Efficacy and Safety of Once-Weekly PB-119 Monotherapy vs. Placebo in Chinese Patients with Type 2 Diabetes in a Randomized Controlled Trial
Authors:   PEGBIO STUDY GROUP, XU MIN , LIANG RUIFANG
Published: June 2023

Background: PB-119 is a novel once-weekly polyethylene glycolated exenatide developed in China for T2DM treatment. Favorable efficacy and safety profile had been demonstrated in two phase 2 studies respectively completed in US and China.

Methods: In this multicenter, double-blind, placebo-controlled, 52-week phase 3 study, 273 drug-naïve Chinese patients with type 2 diabetes were randomized (1:1) to receive subcutaneous PB-119 150ug once weekly or volume-matched placebo once weekly for 24 weeks, followed by 28-week extension during which all the patients were treated with PB-119 150ug once weekly. The primary endpoint was the HbA1c change from baseline to week 24. ClinicalTrials.gov, NCT04504370

Results: At week 24, HbA1c showed a significantly decrease with PB-119 (-1.35%) than placebo (-0.51%, p<0.001). Significant more patients reached the target of HbA1c less than 7.0% in the PB-119 group versus the placebo group (50.4% vs 14.2%; p<0.001). Significant greater reduction in FPG (-1.26mmol/L vs. -0.52mmol/L) and PPG (-2.52 vs. -0.85mmol/L) were achieved (P<0.001). The remarkable glycemic lowering effect sustained till the end of week 52. Meanwhile, Insulin, C-peptide and HOMA-ß were significantly increased with PB-119 versus placebo. HOMA-IR was significantly reduced with PB-119 compared with placebo. Significant improvement of blood pressure and blood lipid profile were demonstrated with PB-119 treatment early from week 8 (TC -0.2mmol/L, LDL-C -0.19mmol/L, DBP -1.8mmHg at week 52, p<0.05 compared to the baseline). Most adverse events were mild and transient. Incidence of nausea (8%) and vomit (5.1%) were low. No Grade 2 or above hypoglycemia (< 3.0mmol/L) occurred.

Conclusion: PB-119 significantly and sustainably improves glycemic control, lipid profile, blood pressure, beta-cell function and insulin resistance, and well tolerated. Dose titration is not needed.

Disclosure

Pegbio study group: n/a. M.Xu: None. R.Liang: None.
79-OR: Targeted Erasure of DNA Methylation by TET3 with C/EBPδ Rewires Adipogenic Execution for Energy Metabolism
Authors: PARK JEU , BUM KIM JAE
Published: June 2023

DNA methylation is one of the key epigenetic modifications in the establishment of cell-type-specific characteristics. However, how DNA methylation is selectively regulated at adipocyte-specific loci during adipogenesis remains unclear. We have demonstrated that the transcription factor, C/EBPδ, and the DNA methylation eraser, TET3, cooperatively control adipocyte differentiation. We performed whole-genome bisulfite sequencing to explore the DNA methylation in adipocyte differentiation. Intriguingly, DNA methylation selectively decreases at adipocyte-specific loci carrying the C/EBP binding motif, which correlates with the activity of adipogenic promoters and enhancers. Mechanistically, we find that C/EBPδ recruits a DNA methylation eraser, TET3, to catalyze DNA demethylation and stimulate the expression of key adipogenic genes. Ectopic expression of TET3 potentiates in vitro and in vivo adipocyte differentiation and restores insulin sensitivity and decreased adipogenic potential, which is observed in aged mice and humans. Together, our study highlights how targeted reprogramming of DNA methylation through cooperative action of the transcription factor C/EBPδ, and the DNA methylation eraser TET3, controls adipocyte differentiation for whole body energy metabolism.

Disclosure

J.Park: None. J.Kim: None.

Funding

National Research Foundation of Korea (2018R1A5A1024340 to J.B.K. and J.P), (2020R1A3B2078617 to J.B.K)